Dysregulated inflammasome activity in intestinal inflammation - Insights from patients with very early onset IBD
- PMID: 36524121
- PMCID: PMC9744759
- DOI: 10.3389/fimmu.2022.1027289
Dysregulated inflammasome activity in intestinal inflammation - Insights from patients with very early onset IBD
Abstract
Inflammatory bowel disease (IBD) is a multifactorial disorder triggered by imbalances of the microbiome and immune dysregulations in genetically susceptible individuals. Several mouse and human studies have demonstrated that multimeric inflammasomes are critical regulators of host defense and gut homeostasis by modulating immune responses to pathogen- or damage-associated molecular patterns. In the context of IBD, excessive production of pro-inflammatory Interleukin-1β has been detected in patient-derived intestinal tissues and correlated with the disease severity or failure to respond to anti-tumor necrosis factor therapy. Correspondingly, genome-wide association studies have suggested that single nucleotide polymorphisms in inflammasome components might be associated with risk of IBD development. The relevance of inflammasomes in controlling human intestinal homeostasis has been further exemplified by the discovery of very early onset IBD (VEO-IBD) patients with monogenic defects affecting different molecules in the complex regulatory network of inflammasome activity. This review provides an overview of known causative monogenic entities of VEO-IBD associated with altered inflammasome activity. A better understanding of the molecular mechanisms controlling inflammasomes in monogenic VEO-IBD may open novel therapeutic avenues for rare and common inflammatory diseases.
Keywords: VEO-IBD; genetics; immunodeficiency; inflammasome; inflammation; pediatrics.
Copyright © 2022 Illig and Kotlarz.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
[Inflammatory bowel diseases and inflammasome].Korean J Gastroenterol. 2011 Dec;58(6):300-10. doi: 10.4166/kjg.2011.58.6.300. Korean J Gastroenterol. 2011. PMID: 22198227 Review. Korean.
-
[Pediatric very early onset inflammatory bowel disease: Role of pathology].Ann Pathol. 2023 Jun;43(3):202-212. doi: 10.1016/j.annpat.2023.02.003. Epub 2023 Feb 28. Ann Pathol. 2023. PMID: 36863899 French.
-
Early-onset inflammatory bowel disease as a model disease to identify key regulators of immune homeostasis mechanisms.Immunol Rev. 2019 Jan;287(1):162-185. doi: 10.1111/imr.12726. Immunol Rev. 2019. PMID: 30565237 Free PMC article. Review.
-
Monogenic diseases associated with intestinal inflammation: implications for the understanding of inflammatory bowel disease.Gut. 2013 Dec;62(12):1795-805. doi: 10.1136/gutjnl-2012-303956. Gut. 2013. PMID: 24203055 Review.
-
Very Early Onset Inflammatory Bowel Disease: A Clinical Approach With a Focus on the Role of Genetics and Underlying Immune Deficiencies.Inflamm Bowel Dis. 2020 May 12;26(6):820-842. doi: 10.1093/ibd/izz259. Inflamm Bowel Dis. 2020. PMID: 31833544 Free PMC article. Review.
Cited by
-
Novel Biomarkers for Inflammatory Bowel Disease and Colorectal Cancer: An Interplay between Metabolic Dysregulation and Excessive Inflammation.Int J Mol Sci. 2023 Mar 22;24(6):5967. doi: 10.3390/ijms24065967. Int J Mol Sci. 2023. PMID: 36983040 Free PMC article.
-
LRRK2 G2019S Promotes Colon Cancer Potentially via LRRK2-GSDMD Axis-Mediated Gut Inflammation.Cells. 2024 Mar 23;13(7):565. doi: 10.3390/cells13070565. Cells. 2024. PMID: 38607004 Free PMC article.
-
A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis.Clin Transl Med. 2023 Nov;13(11):e1471. doi: 10.1002/ctm2.1471. Clin Transl Med. 2023. PMID: 37962000 Free PMC article. Clinical Trial.
-
Immunogenicity and Loss of Effectiveness of Biologic Therapy for Inflammatory Bowel Disease Patients Due to Anti-Drug Antibody Development.Antibodies (Basel). 2024 Feb 26;13(1):16. doi: 10.3390/antib13010016. Antibodies (Basel). 2024. PMID: 38534206 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources